Inhibrx Biosciences Inc. (INBX)
13.74
0.49 (3.70%)
At close: Mar 03, 2025, 12:22 PM
No 1D chart data available
| Bid | 13.73 |
| Market Cap | 198.9M |
| Revenue (ttm) | 1.62M |
| Net Income (ttm) | 1.54B |
| EPS (ttm) | 119.39 |
| PE Ratio (ttm) | 0.12 |
| Forward PE | -1.82 |
| Analyst | n/a |
| Ask | 13.84 |
| Volume | 54,052 |
| Avg. Volume (20D) | 84,924 |
| Open | 13.14 |
| Previous Close | 13.25 |
| Day's Range | 13.05 - 13.90 |
| 52-Week Range | 10.80 - 18.95 |
| Beta | -1.11 |
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 4, 2024
Employees 166
Stock Exchange NASDAQ
Ticker Symbol INBX
Website https://inhibrx.com
3 months ago · seekingalpha.com
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformINBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing p...